Topical medication

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Retrieved on:

Tuesday, February 27, 2024

Vitiligo, Therapy, BET, Topical medication, Pharmaceutical industry

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201

Key Points:

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201
BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentation featuring positive data from the Phase 1b trial of VYN201 in vitiligo at the 2024 Global Vitiligo Foundation Annual Scientific Symposium taking place in San Diego on March 7, 2024.
“We are pleased to have this opportunity to present the data from our Phase 1b trial with the vitiligo community at the Global Vitiligo Foundation Annual Scientific Symposium,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE.
“The positive clinical data from the Phase 1b trial supports the advancement of VYN201 into a Phase 2b trial that we expect to initiate next quarter.”
A Phase 1 Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of a Topical Pan-BD BET Inhibitor (VYN201) in Subjects with Active Non-Segmental Vitiligo (session #4)

Boudreaux's® Butt Barrier® Ointment Awarded 2024 Product of the Year

Retrieved on:

Friday, February 9, 2024

Trust, Pediatrics, Skin, Associate, Irritation, Safety, Topical medication, Kantar, Parent, Prestige Consumer Healthcare, Butt, Dermatitis, Petroleum jelly

TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar. The Product of the Year USA Award is one of the most respected honors in the consumer goods industry, celebrating excellence in product innovation and quality. Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability.

Key Points:

TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar.
Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability.
Developed with the utmost care and expertise by Boudreaux's Butt Paste's team of experts, Boudreaux's Butt Barrier® Ointment offers a unique blend of ingredients designed to create a protective barrier against wetness and irritation.
The Butt Barrier® Ointment is clinically tested, hypoallergenic, fragrance free and has been accepted by the National Eczema Association.

Eirion Therapeutics to Present at the 2024 IMCAS WORLD CONGRESS

Retrieved on:

Friday, February 2, 2024

World Congress, MD, Dermatology, Congress, Therapy, Topical medication

WOBURN, Mass., Feb. 2, 2024 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris.

Key Points:

WOBURN, Mass., Feb. 2, 2024 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris.
"IMCAS is one of the premiere aesthetic conferences in the world, and I am excited to showcase Eirion's botulinum product candidates and pipeline progress to my global industry colleagues," commented Dr. Edelson.
IMCAS congresses are medical research conferences focused on providing plastic surgeons and dermatologists with the latest academic and industry updates for their professional progress in the aesthetic field.
IMCAS Paris kicks off the IMCAS congress schedule for the year.

SEC Office of the Investor Advocate Publishes Its Policy Recommendations on Mandatory Arbitration and Registered Index-Linked Annuities Research

Retrieved on:

Tuesday, December 5, 2023

Policy, Comprehension, Topical medication, Metric, Fiscal, Congress, Office, Human, Empirical research, Commission, Security (finance), Financial adviser

Washington, D.C.--(Newsfile Corp. - December 5, 2023) - The Office of the Investor Advocate of the Securities and Exchange Commission today published its Report on Activities for the Fiscal Year 2023 to Congress.

Key Points:

Washington, D.C.--(Newsfile Corp. - December 5, 2023) - The Office of the Investor Advocate of the Securities and Exchange Commission today published its Report on Activities for the Fiscal Year 2023 to Congress.
The report highlights the work of the Office during the fiscal year.
Notable highlights from the report include:
Empirical research findings about investors’ comprehension of registered index-linked annuities as well as policy recommendations;
Research findings about investment advisory agreements use of mandatory arbitration clauses including suggested approaches on combating abusive use of those clauses;
Metrics measuring the activities of the Office including the substantial uptick in investor engagement, investor submissions, and inquiries; and
Topical discussions of private markets, cybersecurity, and equity market structure.
The Office of the Investor Advocate is an independent office within the SEC, created by Congress, to provide investors with a voice inside the Commission, to assist retail investors, to study investor behavior, and to support the Investor Advisory Committee of the Commission.

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Retrieved on:

Monday, November 13, 2023

Webcast, Pancreatic cancer, MK2, Safety, Therapy, Clinical trial, Patient, ACR20, Rheumatoid arthritis, ACRS, Pharmacokinetics, Ulcerative colitis, Atopic dermatitis, Topical medication, Toxic leukoencephalopathy, Osteoporosis, MTX, Pharmaceutical industry, Czech Republic

WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202).

Key Points:

The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment.
Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris’ ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
“We are deeply disappointed with the results of this trial and for patients suffering from rheumatoid arthritis.
Aclaris is supporting Washington University in a first-in-human investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies.

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

Retrieved on:

Friday, September 29, 2023

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.

Key Points:

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.
Results support the feasibility of TTFields therapy delivery to the lungs regardless of BMI and highlight the importance of choosing the appropriate array size for each patient.
“We are committed to continuous innovation, and we look forward to sharing new insights about the use of TTFields therapy with the scientific community,” said Pritesh Shah, Novocure’s Chief Growth Officer.
Tumor Treating Fields (TTFields) in the Real World for Newly Diagnosed Glioblastoma: A Survival Meta-analysis With Systematic Review.

GSE Services Support Topical Report for using Data Validation and Reconciliation for Measurement Uncertainty Recapture

Retrieved on:

Monday, September 25, 2023

Workforce, GSE Systems, Nuclear Regulatory Commission, DVR, Engineering, NRC, Topical medication, Data validation and reconciliation, Plant, Measurement uncertainty, Safety, GSE, Renewable energy

COLUMBIA, Md., Sept. 25, 2023 /PRNewswire/ -- GSE Solutions ("GSE Systems, Inc." or "GSE") (Nasdaq: GVP), a leader in advanced engineering and workforce solutions that supports the future of clean-energy production and decarbonization initiatives for the nuclear power industry, announced that it has developed key services that support recent Topical Report, which outlines the requirements for using Data Validation and Reconciliation (DVR) for Measurement Uncertainty Recapture (MUR).

Key Points:

COLUMBIA, Md., Sept. 25, 2023 /PRNewswire/ -- GSE Solutions ("GSE Systems, Inc." or "GSE") (Nasdaq: GVP), a leader in advanced engineering and workforce solutions that supports the future of clean-energy production and decarbonization initiatives for the nuclear power industry, announced that it has developed key services that support recent Topical Report, which outlines the requirements for using Data Validation and Reconciliation (DVR) for Measurement Uncertainty Recapture (MUR) .
In July 2023, the Nuclear Regulatory Commission (NRC) released the final safety evaluation of the Topical Report submitted for applying DVR to MUR uprates.
DVR is the new elite standard for optimizing plant performance in the nuclear power industry and can now be used to implement uprates of up to approximately 1.4%.
Then, the GSE team uses data analytics to monitor, troubleshoot, and make operational improvements that increase plant output and ensure efficient and safe operations, providing significant economic benefits to the utility.

New Enhancements and Advancements in the Companion Animal Ear Infection Treatment Market 2023-2030 - ResearchAndMarkets.com

Retrieved on:

Wednesday, August 23, 2023

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.

Key Points:

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.
Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Animal Ear Infection Treatment Market?
What is the market share of the leading vendors in the Global Companion Animal Ear Infection Treatment Market?
What modes and strategic moves are considered suitable for entering the Global Companion Animal Ear Infection Treatment Market?

North America Dental Anesthesia Market Analysis/Forecasts 2023-2030 - Rising Incidence of Dental Problems and Growing Demand for Cosmetic Dentistry to Fuel Growth - ResearchAndMarkets.com

Retrieved on:

Wednesday, July 19, 2023

Furthermore, an increase in dental care services coupled with a surge in the number of dental clinics, and an increase in dental care expenditure also remain promising drivers.

Key Points:

Furthermore, an increase in dental care services coupled with a surge in the number of dental clinics, and an increase in dental care expenditure also remain promising drivers.
Moreover, an increase in the frequency of people seeking routine dental care, especially older adults, and growing demand for cosmetic dentistry are some of the major factors expected to contribute to growth over the forecast period.
The factors such as preventive approaches toward dental anesthesia & hygiene, growing R&D activities in dentistry, and increasing disposable income are expected to boost the market growth.
Based on the type segment, local dental anesthesia dominated the dental anesthesia market in terms of revenue with a market share of 64.3% in 2022.

Can I put cortisone on my face? The right advice on creams to fix irritated skin

Retrieved on:

Tuesday, June 20, 2023

Topical corticosteroids, also referred to as corticosteroids or cortisone, are the go-to treatment for many skin disorders including eczema, dermatitis and psoriasis.

Key Points:

Topical corticosteroids, also referred to as corticosteroids or cortisone, are the go-to treatment for many skin disorders including eczema, dermatitis and psoriasis.
They can be found in various forms such as creams, ointments, and solutions.
Topical corticosteroids come in different strengths, from mild (such as 0.5% Hydrocortisone, available over the counter) to very potent prescription formulations.

‘Use sparingly’

Such warnings ignore the fact many patients are prescribed modest-strength topical steroids, which are safe and effective when used properly.
From the patient’s perspective, the current warnings lump all steroids together regardless of their potential for side effects.

Mixed messages

Or hit the problem hard with a stronger concentration for less time?
If cortisone is extensively used, it is advised adults and children should be examined yearly for side effects.
Skin atrophy (or deterioration) is the most common side effect of topical corticosteroids and manifests as tiny degenerative alterations within a few weeks.

Skin thinning

Repeated use in the same spot on the body results in alterations to the skin’s connective tissue and epidermal thinning.
That can result in lax, translucent, wrinkled skin as well as striae (stretch marks), fragility, hypo-pigmentation (fading) and the prominence of underlying veins.
The good news is that once topical corticosteroids are stopped, short-term atrophy from treatment can be reversed, although skin normalisation may take months.

Can you use it safely on your face?

Using strong cortisone creams or ointments on the face can lead to steroid dependence.
Topical steroids on the face can cause symptoms sometimes referred to as “red face syndrome”, dermatitis rosaceaformis steroidica or steroid addiction.
And stopping steroid use on the face after an extended period can have considerable rebound effects including erythema (redness), burning and scaling.

The bottom line

To avoid skin damage, corticosteroids should only be used on skin affected by a skin disease.
Finally, treatment should be customised based on the person’s symptoms, the body parts affected and how long treatment might be required.
This article reflects the views of the author and
should not be construed to represent views or
policies.